Examples of using Normal hepatic function in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
The pharmacokinetics of TMZ were comparable in patients with normal hepatic function and in those with mild or moderate hepaticimpairment.
The maximum concentration and exposure was similar to that observed after subjects with normal hepatic function received an efficacious avanafil 100 mg dose.
moderate(Child-Pugh B) hepatic impairment and subjects with normal hepatic function.
and in subjects with normal hepatic function.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 154% and 87%, respectively in cirrhotic subjects compared to subjects with normal hepatic function.
was twice that found in 8 subjects with normal hepatic function.
compared to subjects with normal hepatic function.
in 8 healthy control subjects with normal hepatic function.
The reduced dose may be escalated to the dose for patients with normal hepatic function if the patient is tolerating the treatment for at least two cycles see sections 4.4 and 5.2.
A single-dose, open-label study was conducted to evaluate the pharmacokinetics of 60 mg lomitapide in healthy volunteers with normal hepatic function compared with patients with mild(Child-Pugh A) and moderate(Child-Pugh B) hepatic impairment.
moderate hepatic impairment were similar as compared to subjects with normal hepatic function.
were similar to that observed in subjects with normal hepatic function.
severe hepatic impairment receiving fosamprenavir with ritonavir compared to matched control subjects with normal hepatic function.
In severely hepatic-impaired subjects, the mean Cmax and AUC adjusted for the 70 mg dose were decreased by 43% and 28%, respectively, compared to subjects with normal hepatic function see sections 4.2 and 4.4.
generally well-tolerated in subjects with mild, moderate, or severe hepatic impairment, and these regimens had similar adverse event and clinical laboratory profiles as previous studies of HIV-1 infected subjects with normal hepatic function.
Compared to control subjects with normal hepatic function, the AUC and Cmax of nelfinavir were not significantly different in subjects with mild impairment
resulting in delayed tmax from about 50 min in subjects with normal hepatic function to about 85 min in patients with moderate
46% higher respectively for subjects with moderate hepatic impairment compared to subjects with normal hepatic function.